HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor | BIOA Stock News

HitGen Inc. partners with BioAge Labs to initiate a Phase 1 clinical study of BGE-102, a novel NLRP3 inhibitor targeting obesity. This milestone triggers a payment to HitGen under their collaboration agreement. BGE-102, developed using HitGen's DEL technology, shows promise in treating age-related inflammation and metabolic disorders. Both companies continue to collaborate on drug discovery programs, leveraging HitGen's advanced screening technology and BioAge's insights into human aging biology.

HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102

HitGen's partner BioAgeLabs, Inc. recently launched a Phase I clinical study of the novel NLRP3 inhibitor BGE-102. This compound was obtained through screening of HitGen's DNA-encoded compound library, and HitGen will receive relevant milestone payments according to the cooperation agreement, with specific amounts not disclosed. BGE-102 is an oral small molecule NLRP3 inhibitor with a novel structure and good brain penetration, aimed at treating obesity

A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%

Innovative drug concept stocks are repeatedly active, Chimin hits the daily limit

Innovative drug concept stocks are repeatedly active, Chimin hit the daily limit, JENKEM rose over 10%, YKYY, Nossan, Frontier Biotechnologies, Salubris, and HitGen followed suit

A-share innovative drug concept stocks rose again, with Chemexpress, HitGen, and Medicilon increasing by over 10%, while Bide and WuXi AppTec also followed suit